Pathophysiology of SARS-CoV-2: the Mount Sinai COVID-19 autopsy experience

Article activity feed

1. Version published to 10.1038/s41379-021-00793-y

   Aug 1, 2021
2. 

   ScreenIT

   Jun 9, 2020

   SciScore for 10.1101/2020.05.18.20099960: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Institutional Review Board Statement	not detected.
   Randomization	not detected.
   Blinding	not detected.
   Power Analysis	not detected.
   Sex as a biological variable	not detected.
   Cell Line Authentication	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   Imunofluorescence: Immunofluorescence studies were performed on 4µm thick formalin-fixed paraffin-embedded tissue slides following antigen retrieval in boiling citrate buffer pH6 (Vector labs), blocking for 1 hour at room temperature (10% normal donkey serum (NDS)/0.5% triton-X (TX)), primary antibody incubation overnight at 4°C with anti-SARS-Cov2 nucleocapsid antibody ((Prosci, 35-579, 1:100) and anti-ACE2 antibody (Abcam, ab15348, 1:500) (1% …

   SciScore for 10.1101/2020.05.18.20099960: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Institutional Review Board Statement	not detected.
   Randomization	not detected.
   Blinding	not detected.
   Power Analysis	not detected.
   Sex as a biological variable	not detected.
   Cell Line Authentication	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   Imunofluorescence: Immunofluorescence studies were performed on 4µm thick formalin-fixed paraffin-embedded tissue slides following antigen retrieval in boiling citrate buffer pH6 (Vector labs), blocking for 1 hour at room temperature (10% normal donkey serum (NDS)/0.5% triton-X (TX)), primary antibody incubation overnight at 4°C with anti-SARS-Cov2 nucleocapsid antibody ((Prosci, 35-579, 1:100) and anti-ACE2 antibody (Abcam, ab15348, 1:500) (1% NDS/0.25% TX)), and species-appropriate Cy3- or A488-conjugated secondary antibody incubation for 4 hours at room temperature (1% NDS/0.25% TX)	anti-SARS-Cov2 nucleocapsid antibody suggested: None anti-ACE2 suggested: (Abcam Cat# ab15348, RRID:AB_301861) ab15348 suggested: (Abcam Cat# ab15348, RRID:AB_301861)
   Experimental Models: Cell Lines
   Sentences	Resources
   Positive controls were prepared from SARS-CoV-2-infected Vero cell lines (gift from Dr. Florian	Vero suggested: CLS Cat# 605372/p622_VERO, RRID:CVCL_0059)

   ---

   Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

   ---

   Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

   ---

   Results from TrialIdentifier: No clinical trial numbers were referenced.

   ---

   Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

   ---

   Results from JetFighter: We did not find any issues relating to colormaps.

   ---

   Results from rtransparent:

   • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
   • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
   • No protocol registration statement was detected.

   ---

   Read the original source
3. 

   Version published to 10.1101/2020.05.18.20099960v1 on medRxiv

   May 22, 2020